10 phenibut tablets at a time. Phenibut - instructions for use
- γ-amino-β-phenylbutyric acid hydrochloride (aminophenylbutyric acid)
- aminophenylbutyric acid
- aminophenylbutyric acid hydrochloride
Composition and release form of the drug
Pills white or white with a slightly yellowish tint, flat-cylindrical in shape, with a chamfer and a notch.
Excipients: lactose monohydrate 180 mg, potato starch 56 mg, 9 mg, calcium stearate monohydrate 5 mg.
10 pcs. - contour cell packaging (2) - cardboard packs.
10 pcs. - contour cell packaging (3) - cardboard packs.
10 pcs. - contour cell packaging (5) - cardboard packs.
Pharmacological action
The nootropic agent is gamma-amino-beta-phenylbutyric acid hydrochloride. Facilitates GABA-mediated transmission of nerve impulses to the central nervous system (direct effect on GABA receptors), and also has an anxiolytic, psychostimulating, antiplatelet and antioxidant effect.
Improves the functional state of the brain by normalizing tissue metabolism and influencing cerebral circulation (increases the volumetric and linear velocity of cerebral blood flow, reduces cerebral vascular tone, improves microcirculation, and has an antiplatelet effect). Helps reduce or eliminate feelings of anxiety, tension, restlessness and fear, normalizes sleep, and has some anticonvulsant effect.
Does not affect cholinergic and adrenergic receptors.
Extends the latent period and shortens the duration and severity of nystagmus.
Reduces manifestations of asthenia and vasovegetative symptoms (including a feeling of heaviness in the head, sleep disturbances, irritability, emotional lability), increases mental performance.
Improves psychological indicators (attention, memory, speed and accuracy of sensory-motor reactions).
When taken as a course, it increases physical and mental performance, improves memory, and normalizes sleep; improves the condition of patients with motor and speech disorders. Patients with asthenia feel better from the first days of therapy; increases interest and initiative (motivation of activity) without sedation and excitement. When used after severe TBI, it increases the number of mitochondria in the perifocal areas and improves the course of bioenergetic processes in the brain.
In case of neurogenic lesions of the heart and stomach, it normalizes the processes of lipid peroxidation. In older people it does not cause workload and excessive lethargy; the relaxing aftereffect is most often absent. Improves microcirculation in the tissues of the eye, reduces the inhibitory effect of ethanol on the central nervous system. Low toxic.
Pharmacokinetics
Absorption is high, penetrates well into all tissues of the body and through the BBB (about 0.1% of the administered dose of the drug penetrates into brain tissue, and in young and elderly people to a much greater extent). Evenly distributed in the liver and kidneys. Metabolized in the liver - 80-95%, metabolites are pharmacologically inactive. Does not accumulate. After 3 hours, it begins to be excreted by the kidneys, while the concentration in the brain tissue does not decrease and it is detected in the brain for another 6 hours. About 5% is excreted by the kidneys unchanged, partially with bile.
Indications
Asthenic and anxious-neurotic states, anxiety, fear, psychopathy. Stuttering and tics in children, enuresis. Urinary retention due to myelodysplasia. Insomnia and nightmares in the elderly. Prevention of anxiety states that arise before surgical interventions and painful diagnostic tests (premedication).
Meniere's disease associated with dysfunctions of the vestibular analyzer of various origins (including otogenic labyrinthitis, vascular and traumatic disorders); prevention of motion sickness during kinetosis.
Primary open-angle (as part of combination therapy).
As an auxiliary therapy in the treatment of alcoholism (for the relief of psychopathological and somatovegetative disorders during withdrawal syndrome).
Treatment of predelirious and delirious states in alcoholism (in combination with conventional detoxification agents).
Contraindications
Hypersensitivity to phenibut.
Dosage
Inside, regardless of food intake. The dose, frequency of administration and duration of treatment depend on the indications, age of the patient, and tolerability. A single dose for adults varies from 20 mg to 750 mg, for children - from 20 mg to 250 mg.
Side effects
From the side of the central nervous system: increased irritability, agitation, anxiety, dizziness, headache, drowsiness.
LP-005934Trade name:
Group name:
Aminophenylbutyric acid
Dosage form:
pills
Composition per tablet
Each tablet contains:
Active ingredient:
Aminophenylbutyric acid hydrochloride - 250 mg (phenibut)
Excipients:
Lactose - 180 mg
Potato starch - 49.25 mg
Povidone K-25 - 15.75 mg
Magnesium stearate - 5 mg
Description
Round, flat-cylindrical tablets with a chamfer and a score, white or yellowish-white in color.
Pharmacotherapeutic group:
Other psychostimulants and nootropics.
ATX code:
Pharmacological properties
Pharmacodynamics
The active substance aminophenylbutyric acid hydrochloride is a derivative of gamma-aminobutyric acid (GABA) and phenylethylamine. It has tranquilizing properties, stimulates memory and learning, increases physical performance, eliminates psycho-emotional tension, anxiety, fear and improves sleep. Does not affect cholinergic and adrenergic receptors. Extends the latent period and shortens the duration and severity of nystagmus. Noticeably reduces the manifestation of asthenia and vasovegetative symptoms, including headache, a feeling of heaviness in the head, sleep disturbance, irritability, emotional lability, increases mental performance, improves well-being, increases interest and initiative, motivation for vigorous activity without sedation or agitation.
Unlike tranquilizers, under the influence of aminophenylbutyric acid, psychological indicators (attention, memory, speed and accuracy of sensory-motor reactions) improve. The formation of addiction and dependence on the drug, or “withdrawal” syndrome, was not noted.
Pharmacokinetics
After oral administration, it is well absorbed and penetrates into all tissues of the body. About 0.1% of aminophenylbutyric acid penetrates into the brain tissue from the dose of the drug; in young and elderly patients, increased penetration through the blood-brain barrier is possible. After 3 hours, aminophenylbutyric acid is detected in the urine, at the same time the concentration in the brain tissue does not decrease; it is detected in the brain after another 6 hours.
80-95% of the drug is metabolized in the liver to pharmacologically inactive metabolites. 5% is excreted unchanged from the body by the kidneys. The day after taking the drug, aminophenylbutyric acid can only be detected in the urine; it is determined in urine two days after administration, but the detectable amount is 5% of the administered dose. The greatest binding of aminophenylbutyric acid occurs in the liver (80%). When taken repeatedly, the drug does not accumulate in the body.
Indications for use
- asthenic and anxiety-neurotic conditions;
- stuttering, tics and enuresis in children;
- insomnia and night anxiety in the elderly;
- Meniere's disease, dizziness associated with dysfunctions of the vestibular analyzer of various origins;
- prevention of motion sickness during kinetosis;
- as part of complex therapy for alcohol withdrawal syndrome, for the relief of psychopathological and somatovegetative disorders.
Contraindications
- hypersensitivity to the active substance or auxiliary components of the drug;
- acute renal failure;
- pregnancy;
- breastfeeding period;
- children under 3 years of age;
- lactase deficiency, lactose intolerance, glucose-galactose malabsorption syndrome.
With caution
Patients with erosive and ulcerative diseases of the gastrointestinal tract are recommended to prescribe smaller doses of the drug due to the irritating effect of the drug.
Use during pregnancy and breastfeeding
Use during pregnancy and breastfeeding is not recommended, since there are not enough clinical observations.
Experimental studies on animals did not establish mutagenic, teratogenic or embryotoxic effects of the drug.
Directions for use and doses
Orally after meals with water. You can't chew it.
Asthenic and anxiety-neurotic conditions
Adults: 250-500 mg (in terms of the required number of tablets) 3 times a day. Highest single doses: for adults - 750 mg (in terms of the required number of tablets), for patients over 60 years old - 500 mg (in terms of the required number of tablets). If necessary, the daily dose is increased to 2500 mg (in terms of the required number of tablets). The course of treatment is 4-6 weeks.
Stuttering, tics and enuresis in children
Children: from 3 to 8 years - 125 mg (in terms of the required number of tablets) 2-3 times a day; from 8 to 14 years - 250 mg (in terms of the required number of tablets) 2-3 times a day; children over 14 years of age - adult doses.
Insomnia and night anxiety in the elderly
250-500 mg (in terms of the required number of tablets) 3 times a day.
To eliminate dizziness due to dysfunction of the vestibular analyzer of infectious origin (otogenic labyrinth) and Meniere's disease
During the period of exacerbation, 750 mg (in terms of the required number of tablets) is prescribed 3 times a day for 5-7 days, with a decrease in the severity of vestibular disorders - 250-500 mg (in terms of the required number of tablets) 3 times a day for 5-7 days, then - 250 mg (in terms of the required number of tablets) 1 time per day for 5 days.
For relatively mild diseases - 250 mg (in terms of the required number of tablets) 2 times a day for 5-7 days, then 250 mg (in terms of the required number of tablets) 1 time per day for 7-10 days .
To eliminate dizziness due to dysfunction of the vestibular analyzer of vascular and traumatic origin
Prescribe 250 mg (in terms of the required number of tablets) 3 times a day for 12 days.
To prevent motion sickness during kinetosis
250-500 mg (in terms of the required number of tablets) once one hour before the intended trip or when the first symptoms of motion sickness appear.
The anti-sickness effect of aminophenylbutyric acid increases with increasing dosage of the drug.
When severe symptoms of motion sickness occur (“uncontrollable” vomiting and others), taking aminophenylbutyric acid orally is ineffective even at a dose of 750-1000 mg (in terms of the required number of tablets).
As part of complex therapy for alcohol withdrawal syndrome in order to relieve psychopathological and somatovegetative disorders
In the first days of treatment, 250-500 mg (in terms of the required number of tablets) are prescribed 3 times a day during the day and 750 mg (in terms of the required number of tablets) at night, with a gradual decrease in the daily dose to the usual for adults. Never take a double dose to replace a missed dose!
Patients with renal and/or liver failure during long-term use should monitor renal and/or liver function indicators.
If liver function is impaired, high doses of the drug can cause hepatotoxicity. Patients are prescribed less effective doses.
Side effect
Aminophenylbutyric acid, like other drugs, can cause side effects that may not affect all patients. In general, the drug is generally well tolerated.
Nervous system disorders:
frequency unknown: drowsiness and increased symptoms (at the beginning of treatment), dizziness, headache.
Gastrointestinal disorders:
frequency unknown: nausea (at the beginning of treatment).
Disorders of the skin and subcutaneous tissues:
rarely: allergic reactions (skin rash, itching).
Disorders of the liver and biliary tract:
frequency unknown: with long-term use of high doses - hepatotoxicity.
If any of the side effects indicated in the instructions get worse or you notice any other side effects not listed in the instructions, tell your doctor.
Overdose
Aminophenylbutyric acid is low toxic. There have been no reports of overdose cases.
Symptoms
Drowsiness, nausea, vomiting, dizziness. With long-term use of high doses, eosinophilia, decreased blood pressure, impaired renal function, and fatty liver may develop (taking more than 7000 mg).
Treatment
Gastric lavage, symptomatic treatment, maintenance of vital functions. There is no specific antidote.
Interaction with other drugs
For the purpose of mutual potentiation, aminophenylbutyric acid can be combined with other psychotropic drugs, reducing the dose of aminophenylbutyric acid and the combined drugs.
Phenibut prolongs and enhances the effect of hypnotic, antipsychotic and antiparkinsonian drugs.
Special instructions
With long-term use (more than 2-3 weeks), it is necessary to monitor peripheral blood counts and liver function tests every 2-3 weeks.
Impact on the ability to drive vehicles and/or operate machinery
During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions, since some patients may experience disorders of the central nervous system, such as drowsiness and dizziness.
Release form
Tablets 250 mg.
10 tablets in a blister pack made of polyvinyl chloride film and printed varnished aluminum foil.
20, 50 tablets per polyethylene polymer jar.
2 blister packs or 1 polymer jar together with instructions for medical use are placed in a cardboard pack.
Storage conditions
In a place protected from light at a temperature not exceeding 25 ° C.
Keep out of the reach of children.
Best before date
3 years.
Do not use after the expiration date stated on the package.
Vacation conditions
According to the recipe.
Registration Certificate Holder
Regana LLC, Russia
127018, Moscow, 3rd Maryina Roshcha Ave., 40, built. 1, floor 2, room II, room 22.
Manufacturer/Organization accepting consumer complaints
V-MIN LLC, Russia
141300, Moscow region, Sergiev Posad, Moskovskoe highway, 68 km
Country of origin
Latvia Republic of Belarus RussiaProduct group
Nervous systemPsychostimulants and nootropics
Release forms
- 10 - contour cell packaging (1) - cardboard packs. 10 - contour cell packaging (2) - cardboard packs. 10 - contour cell packaging (3) - cardboard packs. 10 - contour cell packaging (1) - cardboard packs. 10 - contour cell packaging (2) - cardboard packs. 10 - contour cell packaging (3) - cardboard packs. 10 - cell packs of 10 pcs. - contour cell packaging (2) - cardboard packs. 50 tablets per pack 250 mg tablets - 20 pcs per pack. pack of 20 tablets pack of 20 tablets
Description of the dosage form
- Round flat-cylindrical tablets of white or white with a slightly yellowish tint, with a chamfer and a score. Tablets Tablets are white or white with a slightly yellowish tint, flat-cylindrical in color. Tablets: white or white with a slightly yellowish tint, flat-cylindrical in shape, beveled and scored
Pharmacological action
Phenibut is a phenyl derivative of GABA and phenylethylamine. It has an anxiolytic effect, reducing tension, anxiety, fear and improving sleep; prolongs and enhances the effect of sleeping pills, narcotic and neuroleptic drugs. Phenibut is a nootropic agent that facilitates GABA-mediated transmission of nerve impulses to the central nervous system (direct effect on GABAergic receptors), and also has an anxiolytic, psychostimulant, antiplatelet and antioxidant effect. , Improves the functional state of the brain by normalizing tissue metabolism and influencing cerebral circulation (increases the volumetric and linear velocity of cerebral blood flow, reduces cerebral vascular resistance, improves microcirculation, and has an antiplatelet effect). Helps reduce or eliminate feelings of anxiety, tension, restlessness and fear, normalizes sleep, and has an anticonvulsant effect. Does not affect cholinergic and adrenergic receptors. Extends the latent period and shortens the duration and severity of nystagmus. Reduces manifestations of asthenia and vasovegetative symptoms (including headache, feeling of heaviness in the head, sleep disturbances, irritability, emotional lability), increases mental performance. Improves psychological indicators (attention, memory, speed and accuracy of sensorimotor reactions). When taken as a course, it increases physical and mental performance, improves memory, and normalizes sleep; improves the condition of patients with motor and speech disorders. In patients with asthenia, from the first days of therapy it improves well-being, increases interest and initiative (motivation of activity) without sedation or agitation. When prescribed after severe traumatic brain injury, it improves the course of bioenergetic processes in the brain. In elderly people, it does not cause depression of the central nervous system; the muscle-relaxing aftereffect is most often absent. Improves microcirculation in the tissues of the eye, reduces the inhibitory effect of ethanol on the central nervous system. The drug is low-toxic, does not cause allergic effects, as well as teratogenic, embryotoxic and carcinogenic effects.Pharmacokinetics
After oral administration, it is well absorbed and penetrates into all tissues of the body. About 0.1% of γ-amino-β-phenylbutyric acid penetrates into the brain tissue from the dose of the drug; in young and elderly patients, increased penetration through the blood-brain barrier is possible. After 3 hours, y-amino-?-phenylbutyric acid is detected in the urine, at the same time the concentration in brain tissue does not decrease; it is detected in the brain after another 6 hours. 80-95% of the drug is metabolized in the liver to pharmacologically inactive metabolites. 5% is excreted unchanged from the body by the kidneys. The day after taking y-amino-?-phenylbutyric acid can only be detected in the urine; it is determined in urine 2 days after administration, but the detectable amount is 5% of the administered dose. The greatest binding of γ-amino-β-phenylbutyric acid occurs in the liver (80%), it is not specific. When taken repeatedly, the drug does not accumulate in the body.Special conditions
Use with caution in case of erosive and ulcerative lesions of the gastrointestinal tract, liver failure. With long-term use, it is necessary to monitor liver function indicators and peripheral blood patterns. Ineffective for severe symptoms of motion sickness (including uncontrollable vomiting, dizziness). Impact on the ability to drive vehicles and operate machinery During the treatment period, it is necessary to refrain from potentially hazardous activities that require increased attention and high speed of psychomotor reactions.Compound
- 1 tab. gamma-amino-beta-phenylbutyric acid hydrochloride 250 mg Excipients: lactose monohydrate 180 mg, potato starch 56 mg, povidone 9 mg, calcium stearate monohydrate 5 mg. Aminophenylbutyric acid hydrochloride 0.25; Auxiliary ingredients: lactose, potato starch, calcium stearate, gelatin phenibut 250 mg; Other ingredients: lactose, potato starch, calcium stearate phenibut 250 mg; Auxiliary ingredients: lactose, potato starch, calcium stearate, phenibut 250 mg; Other ingredients: lactose, potato starch, calcium stearate
Phenibut indications for use
- Asthenic and anxious-neurotic states, anxiety, fear, obsessive-compulsive neurosis, psychopathy. Stuttering and tics in children, enuresis. Urinary retention due to myelodysplasia. Insomnia and nightmares in the elderly. Prevention of anxiety states that arise before surgical interventions and painful diagnostic tests (premedication). Meniere's disease, dizziness associated with dysfunctions of the vestibular analyzer of various origins (including otogenic labyrinthitis, vascular and traumatic disorders); prevention of motion sickness during kinetosis. Primary open-angle glaucoma (as part of combination therapy). As an auxiliary therapy in the treatment of alcoholism (for the relief of psychopathological and somatovegetative disorders during withdrawal syndrome). Treatment of predelirious and delirious states in alcoholism (in combination with conventional detoxification agents
Phenibut contraindications
- Hypersensitivity to phenibut. Use during pregnancy and lactation Use with caution during pregnancy and lactation. Use for liver dysfunction Use with caution in liver failure.
Phenibut dosage
- 0.25 g 250 mg 250 mg
Phenibut side effects
- Like other medicines, aminobutyric acid may cause side effects that may not occur in all patients. Aminobutyric acid is generally well tolerated. Classification of adverse reactions by frequency of development: very common (> 10%); frequent > 1 but 0.1 but 0.01 but 0.1%)); very rare (
Drug interactions
For the purpose of mutual potentiation, phenibut can be combined with other psychotropic drugs, reducing the doses of phenibut and the drugs combined with it. Extends and enhances the effect of sleeping pills, narcotic, neuroleptic and anticonvulsant drugs, alcohol. There is evidence of an increase in the effect of antiparkinsonian drugs under the influence of phenibut.Overdose
Aminophenylbutyric acid is low toxic. There have been no reports of overdose cases. Symptoms Drowsiness, nausea, vomiting, dizziness. With long-term use of high doses, eosinophilia, decreased blood pressure, renal impairment, and fatty liver may develop (taking more than 7 g). Treatment. Gastric lavage, symptomatic treatment, maintenance of vital functions. There is no specific antidote.Storage conditions
- keep away from children
- store in a place protected from light
Composition and release form
1 tablet contains the active substance: aminophenylbutyric acid - 250 mg. There are 10 tablets in a package.
Pharmacological action
The nootropic agent is gamma-amino-beta-phenylbutyric acid hydrochloride. Facilitates GABA-mediated transmission of nerve impulses to the central nervous system (direct effect on GABA receptors), and also has an anxiolytic, psychostimulating, antiplatelet and antioxidant effect.
Improves the functional state of the brain by normalizing tissue metabolism and influencing cerebral circulation (increases the volumetric and linear velocity of cerebral blood flow, reduces cerebral vascular tone, improves microcirculation, and has an antiplatelet effect). Helps reduce or eliminate feelings of anxiety, tension, restlessness and fear, normalizes sleep, and has some anticonvulsant effect.
Does not affect cholinergic and adrenergic receptors.
Extends the latent period and shortens the duration and severity of nystagmus.
Reduces manifestations of asthenia and vasovegetative symptoms (including headache, feeling of heaviness in the head, sleep disturbances, irritability, emotional lability), increases mental performance.
Improves psychological indicators (attention, memory, speed and accuracy of sensory-motor reactions).
When taken as a course, it increases physical and mental performance, improves memory, and normalizes sleep; improves the condition of patients with motor and speech disorders. Patients with asthenia feel better from the first days of therapy; increases interest and initiative (motivation of activity) without sedation and excitement. When used after severe TBI, it increases the number of mitochondria in the perifocal areas and improves the course of bioenergetic processes in the brain.
In case of neurogenic lesions of the heart and stomach, it normalizes the processes of lipid peroxidation. In older people it does not cause workload and excessive lethargy; the relaxing aftereffect is most often absent. Improves microcirculation in the tissues of the eye, reduces the inhibitory effect of ethanol on the central nervous system. Low toxic.
Pharmacokinetics
Absorption is high, penetrates well into all tissues of the body and through the BBB (about 0.1% of the administered dose of the drug penetrates into brain tissue, and in young and elderly people to a much greater extent). Evenly distributed in the liver and kidneys. Metabolized in the liver - 80-95%, metabolites are pharmacologically inactive. Does not accumulate. After 3 hours, it begins to be excreted by the kidneys, while the concentration in the brain tissue does not decrease and it is detected in the brain for another 6 hours. About 5% is excreted by the kidneys unchanged, partially with bile.
Clinical pharmacology
Nootropic drug with anxiolytic activity
Indications for use
Asthenic and anxious-neurotic states, anxiety, fear, obsessive-compulsive neurosis, psychopathy. Stuttering and tics in children, enuresis. Urinary retention due to myelodysplasia. Insomnia and nightmares in the elderly. Prevention of anxiety states that arise before surgical interventions and painful diagnostic tests (premedication).
Meniere's disease, dizziness associated with dysfunctions of the vestibular analyzer of various origins (including otogenic labyrinthitis, vascular and traumatic disorders); prevention of motion sickness during kinetosis.
Primary open-angle glaucoma (as part of combination therapy).
As an auxiliary therapy in the treatment of alcoholism (for the relief of psychopathological and somatovegetative disorders during withdrawal syndrome).
Treatment of predelirious and delirious states in alcoholism (in combination with conventional detoxification agents).
Contraindications for use
Hypersensitivity to phenibut.
Use during pregnancy and children
Use with caution during pregnancy and lactation.
Side effects
From the side of the central nervous system: increased irritability, agitation, anxiety, dizziness, headache, drowsiness.
From the digestive system: nausea (at first doses).
Allergic reactions: skin rash, itching.
Drug interactions
Extends and enhances the effect of sleeping pills, narcotic analgesics, antiepileptic, antipsychotic and antiparkinsonian drugs.
Dosage
Inside, regardless of food intake. The dose, frequency of administration and duration of treatment depend on the indications, age of the patient, and tolerability. A single dose for adults varies from 20 mg to 750 mg, for children - from 20 mg to 250 mg.
Overdose
Symptoms: with long-term use in a daily dose of 7-14 g, hepatotoxicity appears, only in the highest dose used - eosinophilia, fatty liver; drowsiness, nausea, vomiting, hypotension, renal failure. Treatment: gastric lavage, measures to maintain vital functions, symptomatic therapy.
Precautions
Use with caution in case of erosive and ulcerative lesions of the gastrointestinal tract, liver failure.
With long-term use, it is necessary to monitor liver function indicators and peripheral blood patterns.
Ineffective for severe symptoms of motion sickness (including uncontrollable vomiting, dizziness).
Impact on the ability to drive vehicles and operate machinery
During the treatment period, it is necessary to refrain from potentially dangerous activities that require increased attention and high speed of psychomotor reactions.
Phenibut
